Drug Details

General Information of the Drug (ID: DR9565)
Name
Fluoxetine
Synonyms
fluoxetine; 54910-89-3; Prozac; Pulvules; Portal; Eufor; Animex-On; Fluoxetina; Fluoxetina [Spanish]; Fluoxetinum; Fluoxetinum [INN-Latin]; Fluoxetina [INN-Spanish]; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; Fontex; Reconcile; Fluctine; Fluoxac; Fludac; Fluxil; Fluoxetin; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; CHEMBL41; dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Symbyax; CHEBI:86990; Selfemra; NSC-283480; (+/-)-Fluoxetine; HSDB 6633; NCGC00015428-08; (+/-) -Fluoxetine; Fluval; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; n-methyl-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine; Fluoxetine-d5 solution; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; DSSTox_CID_3067; DSSTox_RID_76861; DSSTox_GSID_23067; Fluoxetine [USAN:INN:BAN]; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; N-methyl-3-[4-(trifluoromethyl)phenoxy]-3-(3-tritiophenyl)propan-1-amine; Fluoxetine (TN); CAS-54910-89-3; Fluoxetine (USAN/INN); methyl{3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl}amine; Benzenepropanamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-; 1173147-79-9; Spectrum_001679; SpecPlus_000723; Prestwick0_000511; Prestwick1_000511; Prestwick2_000511; Prestwick3_000511; Spectrum2_001658; Spectrum3_001648; Spectrum4_000613; Spectrum5_001518; Benzenepropamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-; Biomol-NT_000152; Epitope ID:224550; (+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; SCHEMBL8353; (+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; Lopac0_000558; BSPBio_000461; BSPBio_003375; GTPL203; KBioGR_001166; KBioSS_002159; cid_62857; DivK1c_006819; SPBio_001815; SPBio_002382; BEN445; BPBio1_000354; BPBio1_000509; CHEBI:5118; DTXSID7023067; BDBM30130; KBio1_001763; KBio2_002159; KBio2_004727; KBio2_007295; KBio3_002595; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; HMS2090H14; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; ALBB-025606; AMY32526; BCP28440; HY-B0102; N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine; Tox21_110144; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; BBL012251; MFCD00072041; NS-140; NSC283480; SBB017267; STK734483; AKOS003663021; Tox21_110144_1; AC-8478; CCG-204648; DB00472; NSC 283480; NSC 758685; SDCCGSBI-0050541.P004; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; NCGC00015428-06; NCGC00015428-07; NCGC00015428-10; NCGC00015428-11; NCGC00015428-12; NCGC00015428-13; NCGC00015428-15; NCGC00015428-27; NCGC00024879-03; NCGC00024879-04; AS-44989; ST076807; SBI-0050541.P003; AB0107059; DB-015148; AB00053774; FT-0626489; D00326; AB00053774-13; AB00053774-14; AB00053774_15; AB00053774_16; L000931; Q422244; BRD-A31159102-001-01-9; BRD-A31159102-003-05-6; BRD-A31159102-003-16-3; LY-110140;LY 110140;LY110140; N-methyl 3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; N-Methyl-3-phenyl-3-(p-trifluoromethylphenoxy)propylamine; Benzenepropanamine, N-methyl-; A-[4-(trifluoromethyl)phenoxy]-; benzenepropanamine, N-methyl-gamma-[4-(trifluoromethyl)phenoxy]-; N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine #; Benzenepropanamine, N-methyl-gamma-[4-(trifluoromethyl)phenoxy]-, (+/-)-; methyl{3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl}amine hydrochloride; N-methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (.+/-.)-N-Methyl-3-phenyl-3-[(.alpha.,.alpha.,.alpha.-trifluoro-p-tolyl)oxy]propylamine; (.+/-.)-N-Methyl-3-phenyl-3-[(.alpha.,la,.alpha.-trifluoro-p-tolyl)oxy]propylamine; Benzenepropanamine, N-methyl-.gamma.-[4-(trifluoromethyl)phenoxy]-, (.+/-.)-; 57226-07-0
    Click to Show/Hide
Molecular Type
Small molecule
Disease Depression [ICD-11: 6A70-6A71] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C17H18F3NO
PubChem CID
3386
Canonical SMILES
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F
InChI
1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
InChIKey
RTHCYVBBDHJXIQ-UHFFFAOYSA-N
CAS Number
CAS 54910-89-3
ChEBI ID
CHEBI:86990
TTD Drug ID
D0TR5X
DrugBank ID
DB00472
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Olanzapine      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical Trial
                    Experimental
                    Result(s)		 Olanzapine/fluoxetine combination demonstrated rapid onset of antidepressant effect (within 7 days) compared to placebo that was sustained over 8 weeks of treatment in a sample of BD patients.
Target and Pathway
Target(s) Serotonin transporter (SERT)  Molecule Info  [3]
KEGG Pathway Serotonergic synapse Click to Show/Hide
NetPath Pathway TCR Signaling Pathway Click to Show/Hide
Panther Pathway 5HT1 type receptor mediated signaling pathway Click to Show/Hide
2 5HT2 type receptor mediated signaling pathway
3 5HT3 type receptor mediated signaling pathway
4 5HT4 type receptor mediated signaling pathway
WikiPathways Monoamine Transport Click to Show/Hide
2 SIDS Susceptibility Pathways
3 NRF2 pathway
4 Synaptic Vesicle Pathway
5 Serotonin Transporter Activity
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 203).
Reference 2 Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord. 2007 Sep;9(6):618-27.
Reference 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link